Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with viral cytopathic effects. A pilot study.
Sixteen patients with cervical intraepithelial neoplasia (CIN), grades 2 and 3, and vulvar intraepithelial neoplasia (VIN), grade 3, associated with human papillomavirus (HPV) infection were treated with human fibroblast interferon (HFI). Treatment consisted of 2-3 X 10(6) IU/day injected intra- and perilesionally for five days per week for two to three weeks with or without topically applied cream (1.2 X 10(6) IU/day for five days). Eight complete and two partial regressions occurred. The duration of the response ranged from 4 to 20 months. Fever, chills and fatigue with or without headache were the side effects. Our preliminary results indicate that HFI was active against CIN and VIN associated with HPV infection.
De Palo
G
G
Stefanon
B
B
Rilke
F
F
Pilotti
S
S
Ghione
M
M
D000328:Adult; D000818:Animals; D002278:Carcinoma in Situ / Q000209:etiology / Q000628:therapy*; D003588:Cytopathogenic Effect, Viral; D005221:Fatigue / Q000209:etiology; D005260:Female; D005334:Fever / Q000209:etiology; D006261:Headache / Q000209:etiology; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D027383:Papillomaviridae; D010865:Pilot Projects; D013997:Time Factors; D014412:Tumor Virus Infections / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000209:etiology / Q000628:therapy*; D014846:Vulvar Neoplasms / Q000209:etiology / Q000628:therapy*
D007370:Interferon Type I